Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 12INDUSTRY 7NIH 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Thoracic 11Breast 10CNS 5Sarcoma 2Gynecologic 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Cyclophosphamide 90Vincristine 83Doxorubicin 69Prednisone 66Cytarabine 59Methotrexate 58Rituximab 49Etoposide 43Radiotherapy 41Dexamethasone 41Filgrastim 39Leucovorin 27Mercaptopurine 26Granulocyte Colony-Stimulating Factor 26pegaspargase 22Calcium Dobesilate 22Daunorubicin 21Asparaginase 20merphos 19Specimen Handling 18Thioguanine 17Hydrocortisone 16Bleomycin 16Peripheral Blood Stem Cell Transplantation 14Vinblastine 13Gene Expression Profiling 13Methylprednisolone 12Ifosfamide 12Gemcitabine 12dexamethasone acetate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Bevacizumab × Lymphoid × Clear all
NCT00217425 2023-06-18

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡